Summary of Key Information:
Reporting Period (Quarter/Year): Quarter 2 and Half Year Ended September 30, 2026
Nature of Filing / Announcement: Outcome of Board Meeting - Financial Results Approval
Audit Opinion:
Clean Opinion - Limited Review Report states nothing has come to their attention that causes them to believe the statement contains any material misstatement.
Key Financial Highlights [Amounts in ₹ Lacs]:
Standalone Results:
Quarter Ended September 30, 2026:
- Revenue from Operations: ₹3,016.91 Lacs (₹30.17 Crore)
- Total Income: ₹3,111.95 Lacs (₹31.12 Crore)
- Net Profit: ₹206.58 Lacs (₹2.07 Crore)
- EPS: ₹0.16 (Basic and Diluted)
Half Year Ended September 30, 2026:
- Revenue from Operations: ₹5,306.05 Lacs (₹53.06 Crore)
- Total Income: ₹5,459.06 Lacs (₹54.59 Crore)
- Net Profit: ₹355.55 Lacs (₹3.56 Crore)
- EPS: ₹0.27 (Basic and Diluted)
Balance Sheet (Standalone) as at September 30, 2026:
- Total Assets: ₹14,096.07 Lacs (₹140.96 Crore)
- Cash and Cash Equivalents: ₹5,860.51 Lacs (₹58.61 Crore)
- Bank Balances (other than cash equivalents): Negative ₹191.89 Lacs (Negative ₹1.92 Crore)
- Total Debt (Borrowings): ₹1,532.37 Lacs (₹15.32 Crore) [Non-current: ₹630.37 Lacs, Current: ₹902.00 Lacs]
- Other Equity: ₹5,552.42 Lacs (₹55.52 Crore)
Consolidated Results:
Half Year Ended September 30, 2026:
- Revenue from Operations: ₹5,306.05 Lacs (₹53.06 Crore)
- Total Income: ₹5,459.06 Lacs (₹54.59 Crore)
- Net Profit: ₹360.30 Lacs (₹3.60 Crore) [Includes share of profit from associate: ₹4.99 Lacs]
- EPS: ₹0.28 (Basic and Diluted)
Balance Sheet (Consolidated) as at September 30, 2026:
- Total Assets: ₹14,113.82 Lacs (₹141.14 Crore)
- Share Capital: ₹2,700.00 Lacs (₹27.00 Crore)
- Other Equity: ₹5,479.41 Lacs (₹54.79 Crore)
Segment-wise Performance:
The company is engaged in the sale of pharmaceutical products and falls within a single business segment. There is no separate reportable segment as per Ind AS 108.
Cash Flow Statement (Half Year Ended September 30, 2026):
- Net Cash from Operating Activities: ₹262.19 Lacs (₹2.62 Crore)
- Net Cash used in Investing Activities: ₹169.45 Lacs (₹1.69 Crore)
- Net Cash used in Financing Activities: ₹395.49 Lacs (₹3.95 Crore)
- Net Decrease in Cash: ₹302.75 Lacs (₹3.03 Crore)
Corporate Actions:
Not Specified
Other Significant Information:
- The company acquired 21.47% equity shares of Kesar Pharma Limited on July 3, 2026, increasing total holding to 41.79%, making it an associate company
- Previous period figures have been regrouped/reclassified to conform to current period presentation
- The company has investments in associates totaling ₹1,468.48 Lacs (₹14.68 Crore)
- Loans given amount to ₹1,450.73 Lacs (₹14.51 Crore) on standalone basis